PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Finan, B. ; Yang, B.* ; Ottaway, N.* ; Smiley, D.L.* ; Ma, T.* ; Clemmensen, C. ; Chabenne, J.* ; Zhang, L.* ; Habegger, K.M.* ; Fischer, K. ; Campbell, J.E.* ; Sandoval, D.A.* ; Seeley, R.J.* ; Bleicher, K.* ; Uhles, S.* ; Riboulet, W.* ; Funk, J.* ; Hertel, C.* ; Belli, S.* ; Sebokova, E.* ; Conde-Knape, K.* ; Konkar, A.* ; Drucker, D.J.* ; Gelfanov, V.* ; Pfluger, P.T. ; Müller, T.D. ; Perez-Tilve, D.* ; DiMarchi, R.D.* ; Tschöp, M.H.

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.

J. Nat. Med. 21, 27-36 (2015)
DOI PMC
Open Access Green as soon as Postprint is submitted to ZB.
We report the discovery of a new monomeric peptide that reduces body weight and diabetic complications in rodent models of obesity by acting as an agonist at three key metabolically-related peptide hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon receptors. This triple agonist demonstrates supraphysiological potency and equally aligned constituent activities at each receptor, all without cross-reactivity at other related receptors. Such balanced unimolecular triple agonism proved superior to any existing dual coagonists and best-in-class monoagonists to reduce body weight, enhance glycemic control and reverse hepatic steatosis in relevant rodent models. Various loss-of-function models, including genetic knockout, pharmacological blockade and selective chemical knockout, confirmed contributions of each constituent activity in vivo. We demonstrate that these individual constituent activities harmonize to govern the overall metabolic efficacy, which predominantly results from synergistic glucagon action to increase energy expenditure, GLP-1 action to reduce caloric intake and improve glucose control, and GIP action to potentiate the incretin effect and buffer against the diabetogenic effect of inherent glucagon activity. These preclinical studies suggest that, so far, this unimolecular, polypharmaceutical strategy has potential to be the most effective pharmacological approach to reversing obesity and related metabolic disorders.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
1.593
5.064
330
372
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords Controlled-release Phentermine/topiramate; Glp-1 Receptor Activation; Triple-acting Agonist; Fat-fed Mice; Glucagon Receptors; Leptin Responsiveness; Hybrid Peptide; Weight-loss; Glucose; Adults
Language english
Publication Year 2015
Prepublished in Year 2014
HGF-reported in Year 2014
ISSN (print) / ISBN 1340-3443
e-ISSN 1861-0293
Journal Journal of natural medicines
Quellenangaben Volume: 21, Issue: 1, Pages: 27-36 Article Number: , Supplement: ,
Publisher Springer
Publishing Place Tokyo [u.a.]
Reviewing status Peer reviewed
Institute(s) Institute of Diabetes and Obesity (IDO)
POF-Topic(s) 30201 - Metabolic Health
90000 - German Center for Diabetes Research
Research field(s) Helmholtz Diabetes Center
PSP Element(s) G-502200-001
G-501900-221
G-502200-011
PubMed ID 25485909
DOI 10.1038/nm.3761
WOS ID WOS:000348408000010
Erfassungsdatum 2014-12-10
[➜Report correction]